Physician profile

Cecilia A Larson

Endocrinology, Diabetes & Metabolism · Needham, MA

NPI 1366539934

$667.33

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Endocrinology, Diabetes & Metabolism

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$67.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $156.40 2019-2022
Novo Nordisk INC $151.82 2019-2023 Ozempic, Rybelsus, Wegovy
Medtronic Minimed, INC. $141.35 2019-2020
Abbott Laboratories $82.22 2019-2020
Medtronic, INC. $40.95 2021-2022
Dexcom, INC. $32.21 2023 Dexcom G6 Transmitter
Lifescan, INC. $26.18 2019
Insulet Corporation $19.22 2020
Astrazeneca Pharmaceuticals LP $16.98 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Cecilia A Larson

$667.33

in general payments reported 2019-2025

Years
2019-2023
Top company
Lilly USA, LLC

https://glasscript.com/doctor/1170780/cecilia-a-larson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.